News

Xiromed LLC Launches Progesterone Vial for Injection 500 mg/10 mL (50mg/mL)

May 2, 2022

Florham Park, NJ, May 2nd, 2022 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Progesterone Injection USP, 500 mg/10 mL (50 mg/mL) Multiple-Dose Vial, generic to Progesterone Injection USP, 50 mg/mL.   Annual market sales for Progesterone Injection USP, 50 mg/mL and its generics for the twelve month period […]


Xiromed® LLC Launches Naftifine Hydrochloride Cream USP, 2%

February 25, 2022

Florham Park, NJ, February 25th, 2022 Xiromed LLC, an Insud Pharma company, today announced the launch of Naftifine Hydrochloride Cream USP, 2%, generic to Naftin®, in partnership with Genzum Life Sciences. “Xiromed continues to execute on its growth plan to deliver quality generics to the US market. The launch of Naftifine Cream further bolsters our […]


Xiromed LLC Launches Sodium Nitroprusside Injection, 50 mg/2 mL (25 mg/mL)

January 24, 2022

Florham Park, NJ, January 24, 2022 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Sodium Nitroprusside Injection, 50 mg/2 mL (25 mg/mL), generic to Nitropress®. Xiromed CEO, Narasimhan Mani commented, “The launch of Sodium Nitroprusside Injection is Xiromed’s latest offering from our pipeline of injectable products and demonstrates […]


Xiromed LLC Launches Docetaxel Injection, USP, 10mg/mL

September 27, 2021

Florham Park, NJ, September 27, 2021 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Fluorouracil Injection 50mg/mL, generic to Adrucil®. Annual market sales for Adrucil® and its generics for the twelve-month period ending June, 2021 were $22.2 million, according to IQVIA™.     Xiromed CEO, Narasimhan Mani commented, “The […]


Xiromed LLC Launches Fluorouracil Injection 50mg/mL

August 12, 2021

Florham Park, NJ, August 12, 2021 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Fluorouracil Injection 50mg/mL, generic to Adrucil®. Annual market sales for Adrucil® and its generics for the twelve-month period ending June, 2021 were $22.2 million, according to IQVIA™.     Xiromed CEO, Narasimhan Mani commented, “The […]


Xiromed LLC Launches Ketoconazole Foam, 2%

August 2, 2021

Florham Park, NJ, August 2, 2021 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Ketoconazole Foam, 2%, generic to Extina®. “This is an exciting day for Xiromed as we launch our first foam product in the US market.  Xiromed is focused on expanding the range of dosage forms […]


Xiromed LLC Launches Tobramycin Vial for Injection, 1.2g

July 13, 2021

Florham Park, NJ, July 13, 2021 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Tobramycin Vial for Injection, 1.2g, generic to Nebcin®. Annual market sales for Nebcin® and its generics for the twelve month period ending April, 2021 were $16 million, according to IQVIA™.                   Xiromed CEO, […]


Xiromed LLC Launches Darifenacin ER Tablets

May 5, 2021

Florham Park, NJ, May 5, 2021 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Darifenacin Extended Release Tablets, generic to Enablex®.  “Xiromed is focused on providing quality generic products to patients in the US and the launch of Darifenacin ER Tablets is the latest example of our commitment […]


Xiromed LLC Launches Omeprazole Delayed Release Capsules, 20mg

March 25, 2021

Florham Park, NJ, March 25, 2021  Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Omeprazole Delayed Release Capsules, 20mg, generic to Prilosec®.  “Xiromed is committed to providing cost effective generic products to our customers, and the launch of Omeprazole Delayed Release Capsules is the latest example of that […]